Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

Bluebird’s gene therapy for brain disease receives accelerated approval

Bluebird Bio Inc.’s gene therapy for a brain-wasting disease received accelerated approval from U.S. regulators, making it the first treatment of its kind for children living with cerebral adrenoleukodystrophy.

Tribune News Service

Congress releases audio of alleged scam in FDA recruitment

MYSURU

The Hindu

FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Maharashtra FDA cancels Johnson & Johnson's baby powder manufacturing licence

The State government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies

The Hindu

1 Stock That’ll Make You Turn Blue in the Face for Owning

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

StockNews.com

California and New York aim to curb diet pill sales to minors

California and New York are on the cusp of going further than the FDA in restricting the sale of non-prescription diet pills to minors as pediatricians and public health advocates try to protect kids from extreme weight-loss gimmicks online.

Tribune News Service

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Experts debunk bizarre celebrity health trends from 'Vampire Facial' to drinking wee

Health professionals hit out at some of the wacky ways stars to stay in top shape - such as Kim Kardashian's face smeared and injected with her own blood.

Daily Record

Bipartisan Lawmakers Call Out FDA's 'Inadequate' Response To Hemp And CBD Regulations

Bipartisan House members sent a letter to the FDA commissioner to complain about the agency's “completely insufficient response” to their bill, which called for hemp-derived CBD to be permitted and regulated as a food additive.

Benzinga

US warns monkeypox could mutate to resist antiviral drug

U.S. health officials are warning doctors against overusing the lone drug available to treat monkeypox

The Independent UK

Outrageous celebrity health trends debunked - from Kim K's 'Vampire Facial' to vaginal sunbathing

Some of the more wild and wacky methods our stars use to stay in tip-top shape are not really such a great idea, warn experts

Daily Mirror

This 1 Stock Pays You Just for Owning It

Leading pharmaceutical company Pfizer (PFE) did exceptionally well during the pandemic thanks to the high demand for its COVID-19 vaccine, and it still has enough growth prospects. The company’s focus on strengthening its pipeline via business acquisitions, product development, and approvals is expected to deliver impressive growth in the upcoming…

StockNews.com

Experts question the role of white mulberry in the death of congressman’s wife

SACRAMENTO, Calif. — Scientists, doctors and pathologists are questioning the Sacramento County coroner’s conclusion that Lori McClintock’s death was related to white mulberry, a plant that has been used as an herbal remedy for centuries — and one that the coroner’s botanical consultant called “not toxic” in a letter to…

Tribune News Service

MAPS Gets A New Partner To Study MDMA Therapy In Patients With PTSD

In recent months, the psychedelics space has been ground for increasing collaborations. In some cases it was to advance scientific studies.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Tribune News Service

FDA issues urgent recall on Medtronic surgical tubes

The U.S. Food and Drug Administration has issued a Class I recall, the agency's most serious category, for certain tracheal tubes made by Medtronic.

Tribune News Service

New ALS drug funded by Ice Bucket Challenge already in use in South Florida trials

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

Salon

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Benzinga

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.

Benzinga

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

StockNews.com

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

Axios

Affordability questions linger around over-the-counter birth control

"There is no single magic bullet to solving all problems with access and affordability issues."

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

Benzinga

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…

By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT

1 … 154 155 156 157

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Bharatiya Janata Party